Navigation Links
Pancreatic cancer patient survival 'significantly higher' with nab-paclitaxel, says TGen-led study
Date:10/19/2013

nced pancreatic cancer patients. Abraxane previously was approved by the FDA for use in the treatment of metastatic breast cancer (2005) and advanced lung cancer (2012).

While it is still uncertain exactly how Abraxane works, Abraxane wraps traditional chemotherapy, paclitaxel, in near-nano sized shells of albumin, a protein that the tumor could recognize as food. Once inside the tumor, the Abraxane may act like a "Trojan Horse" to release chemotherapy and kill the cancer cells.

Participants treated with Abraxane plus gemcitabine lived, on average, 1.8 months longer than those treated with gemcitabine alone, and they experienced a delay in tumor growth (progression-free survival) that was, on average, 1.8 months later than the participants who only received gemcitabine.

Of note, 35 percent of patients who also received Abraxane survived more than 1 year, a 59 percent increase over the 22 percent of those receiving only gemcitabine who survived more than 1 year. Also, more than twice as many patients (9 percent) who also received Abraxane survived more than 2 years, compared to those (4 percent) who only received gemcitabine.

"This a major breakthrough, but there is more work to be done. Building on these results, we are evaluating new targeted agents in combination with the Abraxane/gemcitabine regimen," said Dr. Ramesh Ramanathan, Medical Director of the Virginia G. Cancer Center Clinical Trials at Scottsdale Healthcare, and MPACT principal investigator for the United States.

The most significant side effect from the addition of nab-paclitaxel was peripheral neuropathy, such as numbness in the hands and feet, although this occurred in only a small proportion of patients and was "rapidly reversible in most patients" by temporarily halting the drug and subsequently reducing its dosage. None of the patients experienced severe (grade 4) neuropathy.

The pancreas is a glandular organ behind the stomach that secretes
'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. New method yields insulin-producing pancreatic cell clusters
2. University of Colorado Cancer Center Study Shows that Bitter Melon Juice Prevents Pancreatic Cancer in Mouse Models
3. No rebirth for insulin secreting pancreatic beta cells
4. Study: FOLFIRINOX Followed by Chemoradiation Shows Substantial Activity in Locally Advanced Pancreatic Cancer
5. Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting
6. Lisa Niemi Swayze And The Pancreatic Cancer Action Network Join More Than 160 Organizations In Asking Congress To Protect Medical Research Funding
7. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
8. Virobays Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
9. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
10. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
11. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Sigma-Aldrich Corporation (NASDAQ: SIAL ... the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in ... 2014, thereby completing the U.S. HSR Act antitrust ... the Company by Merck KGaA, Darmstadt, Germany.  ... to closing the transaction, which remains subject to ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) — ... online medical bill review and advocacy service, has signed ... FREE WellCard Savings discount health services marketplace. ... was more than they expected to pay. As part ... care costs, WellCard Savings is pleased to offer medical ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Bioject ... developer and manufacturer of needle-free injection technology, today ... with Immunomic Therapeutics, Inc. (“ITI”) for ITI to ... with its LAMP™ vaccine platform. , In ... exclusive Worldwide license to the Biojector®-2000 that triggers ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... Gastrotomy Closure Considered Largest Hurdle in Adoption of Incisionless ... Translumenal Endoscopic Surgery (NOTES), SAN CLEMENTE, Calif., Dec. ... field of Incisionless Surgery, today announced that,its EndoSurgical Operating ... a gastrotomy (an incision in the stomach wall) during,a ...
... Protocol Assessment for Reviroc, AMSTERDAM, December 19 ... completed an End of Phase II meeting for ... Reviroc is under,development for elimination of cancer cells ... end-stage blood cancer patients. The FDA,agreed that the ...
... Inc., (Amex:,ADL), today announced that its subsidiary, Jade ... nutraceutical,diagnostic, consumer healthcare and personal care products, is ... Personal Care Center in Hangzhou,China. The state-of-the-art facility ... flagship JPGreen Health and Personal Care Center., ...
Cached Biology Technology:USGI Medical Demonstrates First System for Gastrotomy Closure in NOTES 2Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc 2AMDL's First Full Service JPGreen Health and Personal Care Center Set to Open in Hangzhou, China 2
(Date:12/22/2014)... , Dec. 22, 2014 Research ... has announced the addition of the ... report to their offering. ... insight provides an overview of the global ... aims to control and monitor piracy by ...
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research and ... addition of the "Micro Market Monitor: North America ... http://photos.prnewswire.com/prnh/20130307/600769 ... grow at a CAGR of 3.6% from 2014 to ... in this market, Canada is ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 ... than the iPhone 5S, Samsung introduces for the ... The Galaxy S5 home button presents ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... Pittsburgh of UPMC have identified a potential target ... trachomatis, the most prevalent sexually transmitted bacterial infection ... Toni Darville, MD, chief of the Division of ... strain of Chlamydia that, when investigated in an ...
... artificial heart-valve replacements face several repeat operations as they ... and must be traded for bigger ones. Researchers at ... growing valves created in the lab from a patients ... published September 11, they describe making pulmonary valves through ...
... critical to how successful treatment can be. Therefore, the ... field, where every small step is of great importance. ... Cellular Proteomics, Uppsala University researchers describe a technique that the ... bodys cells and tissues, and our knowledge of the human ...
Cached Biology News:Study by Pittsburgh researchers identifies possible vaccine target for chlamydia 2A step toward tissue-engineered heart structures for children 2